Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets

International Journal of Cancer

Volumn 99, Issue 2, 2002, Pages 157-166

  Vihinen, Pia ^a,b   Kähäri, Veli Matti ^a,c  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Cancer; Invasion; Matrix metalloproteinase; Metastasis; MMP inhibitor; Prognosis

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; AE 941; BATIMASTAT; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CGS 27023A; CLODRONIC ACID; GEMCITABINE; IBANDRONIC ACID; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; MMI 270B; PACLITAXEL; PAMIDRONIC ACID; PLATINUM; PRINOMASTAT; REBIMASTAT; SOLIMASTAT; TANOMASTAT; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ZINC; ZOLEDRONIC ACID;

ARTHRALGIA; BONE PAIN; CANCER; CANCER INVASION; CLINICAL TRIAL; ENZYME INHIBITION; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; MYALGIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; SHORT SURVEY; TUMOR GROWTH; TUMOR VASCULARIZATION;

CELL TRANSFORMATION, NEOPLASTIC; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; METALLOENDOPEPTIDASES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037052641     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10329     Document Type: Short Survey

References (165)

1. Matrix metalloproteinases
2. Matrix metalloproteinase degradation of extracellular matrix: Biological consequences
3. Regulation of matrix metalloproteinase expression in tumour invasion
4. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas
5. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck
6. Human collagenase-3 is expressed in malignant squamous epithelium of the skin
7. Collagenase-3 (MMP-13) is expressed by tumour cells in invasive vulvar squamous cell carcinomas
8. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas
9. High collagenase-1 expression correlates to favourable chemoimmunotherapy response in human metastatic melanoma
10. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor
11. Expression of collagenase-3 (matrix metalloproteinase-13) in transitional cell carcinoma of the urinary bladder
12. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas
13. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages
14. Expression of human macrophage metalloelastase (MMP-12) by tumour cells in skin cancer
15. Matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium
16. Regulation of intestinal α-defensin activation by the metalloproteinase matrilysin in innate host defense
17. Matrilysin-2, a new matrix metalloproteinase expressed in human tumours and showing the minimal domain organization required for secretion, latency and activity
18. Membrane-type matrix metalloproteinases
19. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast and head and neck carcinomas
20. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location and tissue distribution
21. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members
22. Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors
23. Furin-dependent intracellular activation of the human stromelysin-3 zymogen
24. Tissue inhibitors of metalloproteinases: Evolution, structure and function
25. Matrix metalloproteinases and their inhibitors in tumour growth and invasion
26. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin
27. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy
28. Experimental metastasis is suppressed in MMP-9-deficient mice
29. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
30. Gelatinolytic activity of matrix metalloproteinase in tumour tissues correlates with invasiveness of oral cancer
31. Expression of matrix metalloproteinase (gelatinase) in TI adenocarcinoma of the lung
32. Prognostic significance of matrix metalloproteinase 2 and 9 in bladder cancer
33. Increased expression of matrix metalloproteinases (mmp)-2, mmp-9 and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer
34. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas
35. Immunohistochemical expression of MMP-2, MMP-9 and TIMP-2 in neuroblastoma: Association with tumour progression and clinical outcome
36. Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation
37. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - A clinicopathologic study using immunohistochemistry and mRNA in situ hybridization
38. Expression of metalloproteinases endometrial stromal sarcoma: Immunohistochemical study using image analysis
39. Expression of membrane type 1-matrix metalloproteinase in laryngeal carcinoma
40. Increased expression of collagenase-3 (MMP-13) and MT1-MMP in eosophageal cancer is related to cancer aggressiveness
41. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma
42. Matrix metalloproteinases: Molecular aspects of their roles in tumour invasion and metastasis
43. The human tumour cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily
44. Activation of fibroblast collagenase-1 expression by tumour cells of squamous cell carcinomas is mediated by p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase-2
45. Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx
46. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in eosophageal squamous cell carcinomas
47. Expression of MMPs, MT-MMP and TIMPs in squamous cell carcinoma of the oral cavity: Correlations with tumour invasion and metastasis
48. Immunohistochemical study of MT-MMP tissue status in gastric carcinoma and correlation with survival analyzed by univariate and multivariate analysis
49. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer
50. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription
51. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness
52. Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism
53. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma
54. Gelatinase A-immunoreactive protein in ovarian lesions - Prognostic value in epithelial ovarian cancer
55. Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma
56. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma
57. Messanger RNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human hepatocellular cancer
58. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder
59. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2 and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer
60. Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer
61. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein - A new prognostic marker in uveal melanoma?
62. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma
63. Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis
64. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9
65. Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumours
66. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma
67. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer
68. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy
69. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension
70. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma
71. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis
72. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma
73. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
74. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysis
75. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I
76. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
77. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity
78. Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: Role in ischemia-induced angiogenesis
79. Promising new developments in cancer chemotherapy
80. AE-941 (Neovastat) induces endothelial cell apoptosis through activation of caspase-3 activity
81. Cytotoxic activity and inhibition of tumour cell invasion by derivatives of a chemically modified tetracycline CMT-3 (COL-3)
82. Role of matrix metalloproteinases in abdominal aortic aneurysms
83. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9)
84. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3)
85. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma
86. Ongoing trials with matrix metalloproteinase inhibitors
87. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase
88. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: Regulation by nitric oxide
89. Gelatinase A and B (MMP-2, MMP-9) in leukaemia: MMP-2 may indicate a good prognosis in AML
90. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma
91. Matrix metalloproteinases expressed in squamous cell carcinoma of the oral cavity: Correlation with clinicopathologic features and neoadjuvant chemotherapy response
92. The clinical significance of MMP-1 expression in eosophageal carcinoma
93. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer
94. Expression of the MMP-1 in human pancreatic carcinoma: Relationship with prognostic factor
95. Prognosis of gastric carcinoma revealed by interactions between tumour cells and basement membrane
96. Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization
97. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystadenocarcinomas: Clinical and prognostic implications
98. Overexpression of matrix metalloproteinase 2 predicts unfavourable outcome in early-stage non-small cell lung cancer
99. The role of the activated form of matrix metalloproteinase-2 in urothelial cancer
100. Progelatinase A mRNA expression in cell lines derived from tumours in patients with metastatic renal cell carcinoma correlates inversely with survival
101. Matrix metalloproteinase-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma
102. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer - A predictor of tumour stage
103. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer
104. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases ratio in recurrence of urothelial cancer after complete resection
105. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer
106. Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma
107. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer
108. Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma
109. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: Clinicopathologic and prognostic significance of matrilysin expression
110. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications
111. Matrix metalloproteinases: Biologic activity and clinical implications
112. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites
113. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis
114. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions
115. Development of matrix metalloproteinase inhibitors in cancer therapy
116. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer
117. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer
118. Marimastat in recurrent colorectal cancer: Exploratory evaluation of biological activity by measurement of carcioembryonic antigen
119. Marimastat in patients with advanced pancreatic cancer: A dose-finding study
120. A randomized phase II pilot trial of adjuvant marimastat (MAR) in patients with early breast cancer
121. Marimastat as first-line therapy for patients with unresectable pancreatic cancer
122. Randomized doubleblind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: An NCIC-CTG and EORTC study
123. A multicenter, randomized, double-blind, placebo (PB) controlled trial of marimastat (MT) in patients with glioblastoma multiforme (GMB) or gliosarcoma (GS) following completion of conventional, first-line treatment
124. A randomized double-blind placebo-controlled study of Marimastat in patients with inoperable gastric adenocarcinoma
125. Phase II study of the matrix metalloproteinase inhibitor prinomastat in patient with progressive breast cancer
126. Interim results of a phase III study of the matrix metalloproteinase inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer (HRPC)
127. Phase III study of the matrix metalloproteinase (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC)
128. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies
129. A comparison between gemcitabine(GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 (9566) in patients (pts) with advanced pancreatic cancer
130. An international multicentre phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/paclitaxel + platinum containing chemotherapy (CT)
131. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MM1270 (CGS27023A), in patients with advanced solid cancer
132. AE-941 (Neovastat) shows an excellent safety profile and appears beneficial in patients with solid tumours: Rationale for the initiation of 2 phase III clinical trials
133. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
134. Pharmacodynamic studies of Col-3, a novel matrix metalloproteinase inhibitor, in patients with advanced cancer
135. Reversible sideroplastic anemia associated with the tetracycline analogue COL-3
136. MMP inhibition and downregulation by biphosphonates
137. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
138. Adjuvant biphosphonate therapy: The future
139. Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice
140. Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the biphosphonate alendronate
141. Matrix metalloproteinase inhibitors: Applications in oncology
142. Clinical studies with matrix metalloproteinase inhibitors
143. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
144. Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms
145. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma
146. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer
147. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma
148. Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer
149. Analysis of MT1-MMP and MMP2 expression in human gastric cancers
150. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: Implications for tumour progression and clinical prognosis
151. Serum matrix metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases-1, -2 in lung cancer - TIMP-1 as a prognostic marker
152. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma
153. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer
154. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma
155. Membrane-type matrix metalloproteinase-1 expression and activation of gelatinase A as prognostic markers in advanced pediatric neuroblastoma
156. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer
157. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian cancer